The Neutrophil-to-Lymphocyte Ratio as a Predictor of Acute Exacerbations Among Patients With COPD in Uganda
- PMID: 38237091
- PMCID: PMC11075344
- DOI: 10.15326/jcopdf.2023.0443
The Neutrophil-to-Lymphocyte Ratio as a Predictor of Acute Exacerbations Among Patients With COPD in Uganda
Abstract
Background: The neutrophil-to-lymphocyte ratio (NLR) is an inexpensive biomarker that potentially predicts acute exacerbations of chronic obstructive pulmonary disease (AECOPDs). We evaluated the association of baseline NLR and respiratory hospitalization risk within one year among chronic obstructive pulmonary disease (COPD) patients in Uganda, a low- and middle-income country.
Methods: A total of 312 COPD patients were followed for one year. Clinical characteristics and exacerbation rates were collected. Poisson regression with robust variance estimators was used to measure the association between NLR and hospital admissions due to COPD exacerbations. Receiver-operator characteristic (ROC) curves and the area under the curve were used to assess the ability of NLR to predict AECOPDs.
Results: The median (Q 1, Q 3) age was 64 years (53, 71). Females comprised 50.96% (n=159) of the cohort, and 71.2% (n=222) of participants had moderate or severe COPD. A total of 9.9% (n=31) of participants experienced a COPD exacerbation during the period of follow-up. At baseline, the median (Q 1, Q 3) NLR ratio among participants who experienced an exacerbation was 1.46 (0.92, 2.33) compared to 1.03 (0.72,1.42) among those who did not experience one during the follow-up period (p=0.002). Using Youden and Liu's methods, the optimal NLR cutoff for predicting COPD exacerbation was 1.17. This cutoff resulted in a ROC curve area of 0.64 (95% confidence interval: 0.56, 0.73).
Conclusion: The NLR could be used as a risk predictor, in low- and middle-income countries, for hospital admissions due to COPD exacerbations. A cutoff of 1.17 was an independent predictor of hospitalization due to acute exacerbations of COPD within one year.
Keywords: COPD; acute exacerbations of COPD; biomarkers; exacerbations; neutrophil lymphocyte ratio.
JCOPDF © 2024.
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Halpin DMG,Celli BR,Criner GJ,et al. The GOLD Summit on chronic obstructive pulmonary disease in low-and middle-income countries. Int J Tuberc Lung Dis. 2019;23(11):1131-1141. doi: https://doi.org/10.5588/ijtld.19.0397 - PubMed
-
- Meghji J,Mortimer K,Agusti A,et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397(10277):928-940. doi: https://doi.org/10.1016/S0140-6736(21)00458-X - PubMed
-
- Celli BR,Fabbri LM,Aaron SD,et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251-1258. doi: https://doi.org/10.1164/rccm.202108-1819PP - PubMed
-
- Awokola BI,Amusa GA,Jewell CP,et al. Chronic obstructive pulmonary disease in sub-Saharan Africa. Int J Tuberc Lung Dis. 2022;26(3):232-242. doi: https://doi.org/10.5588/ijtld.21.0394 - PMC - PubMed
-
- Adeloye D,Song P,Zhu Y,Campbell H,Sheikh A,Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447-458. doi: https://doi.org/10.1016/S2213-2600(21)00511-7 - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources